Potential Inhibition of COVID-19-driven Pneumonia by Immunosuppressive Therapy and anti-TNFα Antibodies: A Case Report

J Crohns Colitis. 2020 Dec 2;14(12):1786-1787. doi: 10.1093/ecco-jcc/jjaa105.

Authors

Reiko Kunisaki¹, Jun Tsukiji², Makoto Kudo³

Affiliations

¹ Inflammatory Bowel Disease Centre, Yokohama City University Medical Centre, Yokohama, Japan.
² Department of Infection Prevention and Control, Yokohama City University Medical Centre, Yokohama, Japan.
³ Respiratory Disease Centre, Yokohama City University Medical Centre, Yokohama, Japan.

No abstract available

Publication types

Case Reports

MeSH terms

COVID-19 / complications
COVID-19 / immunology*
COVID-19 / physiopathology
COVID-19 / prevention & control
Colitis, Ulcerative / complications
Colitis, Ulcerative / drug therapy*
Colitis, Ulcerative / immunology
Humans
Immunosuppressive Agents / therapeutic use*
Infliximab / therapeutic use*
Male
Middle Aged
Patient Acuity
Tumor Necrosis Factor-alpha / immunology*

Substances

Immunosuppressive Agents
TNF protein, human
Tumor Necrosis Factor-alpha
Infliximab